In a new study, artificial intelligence in the form of ChatGPT outperformed an expert rhinoplasty surgeon in answering preoperative and postoperative patient questions related to nasal surgery.
Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D
Pemvidutide (2.4 mg), an investigational GLP-1/glucagon dual receptor agonist, helped people with obesity achieve an average 15.6% weight loss after 48 weeks in the phase